🎉 M&A multiples are live!
Check it out!

Myomo Valuation Multiples

Discover revenue and EBITDA valuation multiples for Myomo and similar public comparables like InfuSystem, Philips, and SmartVest.

Myomo Overview

About Myomo

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).


Founded

2004

HQ

United States of America
Employees

185

Website

myomo.com

Financials

LTM Revenue $39.8M

LTM EBITDA -$4.5M

EV

$93.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Myomo Financials

Myomo has a last 12-month revenue (LTM) of $39.8M and a last 12-month EBITDA of -$4.5M.

In the most recent fiscal year, Myomo achieved revenue of $32.6M and an EBITDA of -$5.4M.

Myomo expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Myomo valuation multiples based on analyst estimates

Myomo P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $39.8M XXX $32.6M XXX XXX XXX
Gross Profit $28.1M XXX $23.2M XXX XXX XXX
Gross Margin 71% XXX 71% XXX XXX XXX
EBITDA -$4.5M XXX -$5.4M XXX XXX XXX
EBITDA Margin -11% XXX -17% XXX XXX XXX
EBIT -$6.3M XXX -$6.2M XXX XXX XXX
EBIT Margin -16% XXX -19% XXX XXX XXX
Net Profit -$6.3M XXX -$6.2M XXX XXX XXX
Net Margin -16% XXX -19% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Myomo Stock Performance

As of May 30, 2025, Myomo's stock price is $3.

Myomo has current market cap of $107M, and EV of $93.6M.

See Myomo trading valuation data

Myomo Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$93.6M $107M XXX XXX XXX XXX $-0.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Myomo Valuation Multiples

As of May 30, 2025, Myomo has market cap of $107M and EV of $93.6M.

Myomo's trades at 2.9x EV/Revenue multiple, and -17.2x EV/EBITDA.

Equity research analysts estimate Myomo's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Myomo has a P/E ratio of -17.0x.

See valuation multiples for Myomo and 12K+ public comps

Myomo Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $107M XXX $107M XXX XXX XXX
EV (current) $93.6M XXX $93.6M XXX XXX XXX
EV/Revenue 2.4x XXX 2.9x XXX XXX XXX
EV/EBITDA -20.6x XXX -17.2x XXX XXX XXX
EV/EBIT -14.8x XXX -15.1x XXX XXX XXX
EV/Gross Profit 3.3x XXX n/a XXX XXX XXX
P/E -17.0x XXX -17.3x XXX XXX XXX
EV/FCF -16.4x XXX -20.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Myomo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Myomo Margins & Growth Rates

Myomo's last 12 month revenue growth is 40%

Myomo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Myomo's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Myomo's rule of X is 89% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Myomo and other 12K+ public comps

Myomo Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 40% XXX 40% XXX XXX XXX
EBITDA Margin -11% XXX -17% XXX XXX XXX
EBITDA Growth -90% XXX n/a XXX XXX XXX
Rule of 40 0% XXX 23% XXX XXX XXX
Bessemer Rule of X XXX XXX 89% XXX XXX XXX
Revenue per Employee XXX XXX $0.2M XXX XXX XXX
Opex per Employee XXX XXX $0.2M XXX XXX XXX
S&M Expenses to Revenue XXX XXX 38% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 15% XXX XXX XXX
Opex to Revenue XXX XXX 90% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Myomo Public Comps

See public comps and valuation multiples for Medical Devices comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
Perspective Therapeutics XXX XXX XXX XXX XXX XXX
SmartVest XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
Senseonics Holdings XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Myomo M&A and Investment Activity

Myomo acquired  XXX companies to date.

Last acquisition by Myomo was  XXXXXXXX, XXXXX XXXXX XXXXXX . Myomo acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Myomo

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Myomo

When was Myomo founded? Myomo was founded in 2004.
Where is Myomo headquartered? Myomo is headquartered in United States of America.
How many employees does Myomo have? As of today, Myomo has 185 employees.
Who is the CEO of Myomo? Myomo's CEO is Mr. Paul R. Gudonis.
Is Myomo publicy listed? Yes, Myomo is a public company listed on ASE.
What is the stock symbol of Myomo? Myomo trades under MYO ticker.
When did Myomo go public? Myomo went public in 2017.
Who are competitors of Myomo? Similar companies to Myomo include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem.
What is the current market cap of Myomo? Myomo's current market cap is $107M
What is the current revenue of Myomo? Myomo's last 12 months revenue is $39.8M.
What is the current revenue growth of Myomo? Myomo revenue growth (NTM/LTM) is 40%.
What is the current EV/Revenue multiple of Myomo? Current revenue multiple of Myomo is 2.4x.
Is Myomo profitable? Yes, Myomo is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Myomo? Myomo's last 12 months EBITDA is -$4.5M.
What is Myomo's EBITDA margin? Myomo's last 12 months EBITDA margin is -11%.
What is the current EV/EBITDA multiple of Myomo? Current EBITDA multiple of Myomo is -20.6x.
What is the current FCF of Myomo? Myomo's last 12 months FCF is -$5.7M.
What is Myomo's FCF margin? Myomo's last 12 months FCF margin is -14%.
What is the current EV/FCF multiple of Myomo? Current FCF multiple of Myomo is -16.4x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.